True Monthly Cost Calculator

What all-in means here

Medication plus any mandatory recurring fee. It is the only basis on which two programmes with different fee structures can be compared, and it is why some figures here are higher than the number on a programme's own homepage.

A tick means we read it at the provider

Rows marked with a tick carry a price we captured from the provider's own material. The rest are third-party figures we have not confirmed and should be treated as indicative.

What the calculation assumes

The standard escalation: four weeks at 2.5 mg, four at 5 mg, then your chosen maintenance dose for the remainder. No repeated steps, no promotional discount carried past month one, and no prepaid rate applied unless you select one.

Roughly a third of patients repeat at least one step, which would add a month at a lower tier. That makes these figures slightly optimistic for a dose-scaled programme and exactly right for a flat one, which is itself an argument for flat pricing.

Why the answer changes when you change the dose

Dose-scaled programmes reprice as you climb; flat programmes do not. The cheapest programme at the 2.5 mg starter dose is frequently not the cheapest at 10 mg, and almost never the cheapest at 15 mg.

Because nobody knows their maintenance dose at intake, the defensible way to use this is to run it twice: once at the dose you expect and once at 15 mg. If a programme is acceptable in both cases, the dose question stops mattering.

What it cannot price

Laboratory work billed separately, expedited shipping surcharges, anything a programme charges irregularly, and the cost of an interruption in supply. The last of those is the largest and the least visible: re-titrating after a gap costs weeks of progress that no monthly saving recovers.

It also cannot price service quality. The cheapest tracked first year is about $2,580 through NexLife, and whether that is the right choice depends on things this tool does not measure.

Nothing here is transmitted

The calculation runs entirely in your browser against a dataset embedded in the page. There is no account, no email gate and no submission. Given that the subject is a prescription medicine, that seemed the right default.

What this calculator assumes

Four weeks at 2.5 mg, four at 5 mg, then your chosen maintenance dose. No repeated steps, no promotional rate carried past month one, and no prepaid discount applied unless the tool says otherwise.

Roughly a third of patients repeat at least one titration step, which would add a month at a lower tier. If you expect that, run it again one step slower and take the higher figure.

Where the numbers come from

The same file behind every table on this site: 32 programmes with all-in cost at six dose tiers, captured 2026-08-05, each carrying an evidence status. Prices marked verified were read on the provider's own page.

Nothing you enter is transmitted anywhere. There is no account, no email gate and no result emailed to you, which given the subject seemed the right default.

What it cannot tell you

Whether a programme ships on time, answers messages, or is clinically appropriate for you. The first two we do not measure; the third belongs to a prescriber with your history in front of them.

Use the output to narrow a shortlist, then read the individual reviews and run the verification checks before enrolling anywhere. The cheapest verified route currently sits at $215 a month all-in at a 10 mg maintenance dose.

Where these calculators sits in the sequence

Order matters more than most guidance admits. Establish coverage first, because a covered prescription under a documented indication beats every cash route here. Then establish the dose you expect to hold. Only then compare prices.

Most people do this backwards — compare prices, enrol, then discover an indication they already qualified for. Tirzepatide has more of those routes than most weight-management drugs: type 2 diabetes, cardiovascular risk reduction, and a liver indication for a narrow population.

The check that costs nothing

Ask which pharmacy fills the prescription and search your state board's licensee register for it. Two minutes, free, and possible for only 4 of the 16 priced programmes because the rest do not name one.

A name and a licence number is the good answer. A category is incomplete but honest. A deflection about proprietary partnerships is the answer.

Why this matters more here than for approved medicines

An approved product has been reviewed before marketing and is made under a federal quality system with supply-chain traceability. A compounded preparation has not been through that review. Its assurance comes from the pharmacy, the state board licensing it, and at good operations batch testing for sterility and potency.

That is a legitimate framework rather than a loophole, and it moves verification work onto you. It is the honest reason the compounded price is lower.

What this page assumes about you

That you are paying cash, that you will hold a maintenance dose rather than a starter dose, and that a difference of a few hundred dollars across a year is worth an hour of reading. If any of those is wrong, the ordering here changes.

Insurance is the biggest one. A covered prescription under a documented indication beats every cash route on this site, and establishing whether you qualify comes before comparing 16 cash prices spanning $215 to $597.

The bias we can see in our own data

We track what programmes publish, so programmes that publish well look better here than programmes that treat pricing as a sales conversation. That is a real bias and we would rather name it than pretend the dataset is neutral.

It cuts a defensible way — a programme unwilling to state a price before an intake has made a choice you should notice — but it is a bias, and 16 tracked programmes appear here with an explanation instead of a number because of it.

What we deliberately do not measure

Shipping reliability, response times, and whether the clinical oversight is any good. None is observable from outside without enrolling, and we did not enrol.

That absence is why there is no rating out of ten anywhere here. A single score would compress price, disclosure, service and clinical depth into one figure and hide the weighting — which is precisely the trick that makes comparison sites feel authoritative while telling you less than a table would.

The usable proxy is what a programme publishes before it has your money, and that is what every disclosure column here records.

The switching cost nobody prices

Moving programmes for a modest saving carries two costs a table cannot show: a supply gap while a new intake is reviewed, and a new prescriber restarting titration rather than continuing your dose.

The second is expensive. Eight to twelve weeks back through the ladder erases most of what a year's saving would have bought. Ask for dose continuation in writing before cancelling anything, and do not cancel until the new programme has shipped.

Why the same molecule sells across a fifteenfold range

The active ingredient is identical whether it arrives as Zepbound at list price or as a compounded preparation at $215 a month. What differs is everything around it: pre-market review, manufacturing under a federal quality system, supply-chain traceability, cold-chain validation, pharmacovigilance and the commercial cost of bringing a drug to market at all.

That is the trade a compounded route asks you to make, and it is a real one in both directions. The approved product carries assurances the compounded one does not. The compounded one is accessible to people for whom the approved product is not, which is not a trivial benefit when the alternative is no treatment.

What is not defensible is presenting the two as equivalent. A compounded preparation is not a cheaper version of Zepbound; it is a different regulatory object containing the same molecule.

The pharmacology behind the fees

Tirzepatide is dosed weekly, ships refrigerated and must not freeze. Those three facts explain most of the fee structures in this market. Weekly dosing means monthly fulfilment cycles and recurring shipping. Refrigeration means insulated packaging, coolant and expedited carriage. Not freezing means the winter and summer failure modes are different and both cost money to mitigate.

A programme charging nothing for shipping has absorbed that cost into the medication price rather than eliminated it. A programme itemising it has not necessarily made you worse off. The only comparison that survives either structure is the all-in monthly figure, which is why it is the only figure this site ranks on.

What stopping does, and why it belongs in a cost calculation

The withdrawal evidence for this drug class is consistent: substantial weight regain follows discontinuation, because the drug suppresses appetite while it is being taken rather than resetting a set point. That is a pharmacological property, not a failure of willpower.

Read as a budgeting question, it means the relevant number is not what a first year costs but what a sustainable year costs, repeated. A programme you can afford for three years at a maintenance dose is a better clinical bet than one you can afford for eight months, even if the second is cheaper on the month you enrol.